Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25742
Title: CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care.
Austin Authors: Hui, Rina;de Boer, Richard;Lim, Elgene;Yeo, Belinda ;Lynch, Jodi
Affiliation: Cancer Care Centre, St George Public Hospital, Kogarah, New South Wales, Australia
Austin Health
Olivia Newton-John Cancer Research Institute
Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
University of Sydney, Sydney, New South Wales, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Epworth-Freemasons Private Hospital, Melbourne, Victoria, Australia
St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia
Garvan Institute of Medical Research, Sydney, New South Wales, Australia
Issue Date: Jan-2021
metadata.dc.date: 2021-01
Publication information: Asia-Pacific Journal of Clinical Oncology 2021; 17 (Suppl 1): 3-14
Abstract: Patients presenting with hormone receptor-positive (HR+ ), human epidermal growth factor receptor 2-negative (HER2- ) metastatic breast cancer (MBC) are usually treated with endocrine therapy (ET), except if there is a concern about endocrine resistance or a need to achieve rapid disease control due to visceral crisis. The combination of CDK4/6 inhibitor + ET has now replaced single-agent ET as the standard first-line treatment; and it can also be considered a standard option in the second-line setting. This review briefly summarizes recently reported efficacy findings from the key phase III clinical trials of CDK4/6 inhibitor + ET in patients with HR+ /HER2- MBC, including evidence that adding a CDK4/6 inhibitor to ET improves overall survival and does so without reducing patients' quality of life. There is still much to learn regarding the use of CDK4/6 inhibitors and how they may be optimally integrated into clinical practice. In particular, there is a need for specific biomarkers that help predict the likelihood of response or resistance to CDK4/6 inhibitor therapy; and for data to guide treatment decisions when a patient's disease progresses on a CDK4/6 inhibitor.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25742
DOI: 10.1111/ajco.13555
PubMed URL: 33506626
Type: Journal Article
Subjects: CDK4/6 inhibitor
HER2-negative
endocrine therapy
hormone receptor-positive
metastatic breast cancer
overall survival
progression-free survival
quality of life
Appears in Collections:Journal articles

Show full item record

Page view(s)

14
checked on May 11, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.